Conference of the International Clinical Hyperthermia Society 2012View this Special Issue
Conference Paper | Open Access
Ortwin Zais, "Lyme Disease and Oncothermia", Conference Papers in Science, vol. 2013, Article ID 275013, 3 pages, 2013. https://doi.org/10.1155/2013/275013
Lyme Disease and Oncothermia
Lyme disease is a tick-borne disease with multiple organ failures, and systemic disorders. Dramatic change becomes apparent in the chronic phase of the disease. Chronic fatigue syndrome, lapse of concentration, depression, joint pain, and muscle pain are a few, but major clinical symptoms characterizing the disease. The human immune system is defenseless. Borrelia uses various mechanisms to escape from immunoattacks or antibiotic therapies. This “stealth phenomenon” needs new therapeutic principles to be interrupted. Our objective in this paper is to study the effect of oncothermia, which is a well-established oncological therapy, on Lyme disease. First, in our present work, we definitely concentrate on the quality of life of the patients.
Lyme borreliosis (LB), or Lyme disease, is transmitted by ticks of the Ixodes ricinus complex. Its manifestations had been documented . The etiologic agent, Borrelia burgdorferi, was first isolated from the vector tick Ixodes dammini (now I. scapularis) . Borrelia burgdorferi is a bacterial species of the Spirochete class of the genus Borrelia, which has a double-membrane envelope . Borrelia burgdorferi is one of the few pathogenic bacteria that can survive without iron, having replaced all of its iron-sulfur cluster enzymes with enzymes that use manganese, thus avoiding the problem many pathogenic bacteria face in acquiring iron. It takes more than 24 hours of attachment for transfer of Borrelia burgdorferi. Huge development was made during the past 20 years understanding Borrelia burgdorferi and its consequent illness. Its microbiology , epidemiology , diagnosis [6, 7], and clinical practices [8–10] are studied in detail.
Clinical symptoms of Lyme disease are serious. We are listing only some major of them as follows: fatigue syndrome, lapse of concentration, depression, joint pain, muscle pain, erythema chronicum, myocarditis, cardiomyopathy, arrhythmia, arthritis, arthralgia, meningitis, neuropathies, and facial nerve palsy.
Borrelia burgdorferi infections have been linked to non-Hodgkin lymphomas, . Oncothermia, well known in cancer therapy , might be an adequate method for treatment of Lyme disease. The applied bioelectromagnetic energy absorption acts on the cellular membrane  and on its regulation , tuning the parameters to the membrane destruction . The applied interaction radiofrequency (RF) range (RF carrier with LF modulation [16, 17]) coupled by impedance (capacitive) mode could act on the cell-membrane states of the bacteria. The huge temperature gradient on the membrane could modify the HSP structure shown by DNA array involving first of all the HSP60 and HSP70 chaperones proteins . Borrelia burgdorferi is especially sensitive on the membrane states of these HSPs [19, 20], so the effect is expected. These experimental results on the special activity of chaperones have to be clarified in more detail in connection with the applied modulation of oncothermia , which also modified the HSP activity , in consequence it could be a useful tuning parameter for selection of the bacteria.
In 12 patients (8 male and 4 female; mean age 55 y, [39 ÷ 76]) suffering from Lyme disease the influence of oncothermia on healing processes was examined in this pilot study. Their medical history was the cohort forming ability. Tick bite was recognized for 75% (9/12) patients and erythema migrans of 50% (6/12), antibiotics pretreatment was made for all (12/12), and the typical symptoms of lyme disease/lyme-neurodisease were registered for all (12/12). All the patients were ELISA positive (12/12) and Western Blot positive (12/12) as well. Lymphocyte Transformation Test (LTT) was positive for 42% (5/12), while Borrelia-IgG in cerebrospinal fluid was positive in 17% (2/12) of the cases. Due to the complicated and very expensive laboratory tests, the effects were measured on the quality of life of the patients. For this measurement a special questionnaire was prepared, concentrating on three questions: general feeling today, feeling physically and feeling psychologically. Evaluation was made in grades on a 1–6 scale (1 = excellent, 6 = inadequate/very bad). This score is generally used for quality of life evaluation in our practice for longer time.
Treatments were done by oncothermia method (EHY3000, Oncotherm GmbH, Germany); the duration was 60 min per session. Treatments were 3 times a week, and all 10 sessions together were provided. The heating protocol was a step-up heating (70/100/130/150 W) with modulation, using electrode 40 × 70 cm area, applying it for the trunk of the patients.
As drug support minocycline and hydroxychloroquine were used when indicated. They were administered orally.
Complementary supportive therapy was applied orally as well: high dose Vitamin C 7.5 gr; Vitamin B12; glutathione; homeopathics to support emunctories; medicated mushrooms (capsule); supplementary like Vitamin D, calcium, magnesium.
In the majority of cases dramatic improvement in physical state occurred, a better response to other therapeutic treatments. Particularly neurological disorders could be influenced positively.
The patient feels as good as never before, can do housekeeping again, and could do her/his work again. Those who were frequently absent from the school after the treatment regularly visited the lessons again and so forth.
Adverse effects were sometimes headache and rarely neuropathic symptoms during the treatment.
Oncothermia is an important module in treatment-concept of Lyme disease. Mechanism of action against stealth development should be objectified. Procedure of oncothermia treatment (power/treatment-time/treatment frequency) should be defined. Synergies with other treatments should be objectified. Oncothermia should become a vital component in therapeutical treatment of lyme disease.
The author acknowledges the discussions, support, and comments made by Professor Andras Szasz.
- K. Weber and H. W. Pfister, “History of Lyme borreliosis in Europe,” in Aspects of Lyme Borreliosis, K. Weber and W. Burgdorfer, Eds., pp. 1–20, Springer, Berlin, Germany, 1993.
- W. Burgdorfer, A. G. Barbour, S. F. Hayes, J. L. Benach, E. Grunwaldt, and J. P. Davis, “Lyme disease—a tick-borne spirochetosis?” Science, vol. 216, no. 4552, pp. 1317–1319, 1982.
- “Structure, function and biogenesis of the Borrelia cell envelope,” in Borrelia: Molecular Biology, Host Interaction and Pathogenesis, D. S. Samuels and J. D. Radolf, Eds., chapter 6, Caister Academic Press, 2010.
- S. K. Singh and H. J. Girschick, “Molecular survival strategies of the Lyme disease spirochete Borrelia burgdorferi,” Lancet Infectious Diseases, vol. 4, no. 9, pp. 575–583, 2004.
- P. Parola and D. Raoult, “Ticks and tickborne bacterial diseases in humans: an emerging infectious threat,” Clinical Infectious Diseases, vol. 32, no. 6, pp. 897–928, 2001.
- B. Wilske and M. E. Schriefer, “Borrelia,” in Mannual of Clinical Microbiology, P. R. Murray, E. J. Baron, J. H. Jorgensen, M. A. Pfaller, and R. H. Yolken, Eds., pp. 937–954, American Society for Microbiology, Washington, DC, USA, 8th edition, 2003.
- J. Bunikis and A. G. Barbour, “Laboratory testing for suspected Lyme disease,” Medical Clinics of North America, vol. 86, no. 2, pp. 311–340, 2002.
- R. B. Nadelman and G. P. Wormser, “Lyme borreliosis,” The Lancet, vol. 352, no. 9127, pp. 557–565, 1998.
- H. Pfister, B. Wilske, and K. Weber, “Lyme borreliosis: basic science and clinical aspects,” The Lancet, vol. 343, no. 8904, pp. 1013–1016, 1994.
- G. Stanek and F. Strle, “Lyme borreliosis,” The Lancet, vol. 362, no. 9396, pp. 1639–1647, 2003.
- M. Guidoboni, A. J. M. Ferreri, M. Ponzoni, C. Doglioni, and R. Dolcetti, “Infectious agents in mucosa-associated lymphoid tissue-type lymphomas: pathogenic role and therapeutic perspectives,” Clinical Lymphoma and Myeloma, vol. 6, no. 4, pp. 289–300, 2006.
- A. Szasz, N. Szasz, and O. Szasz, Oncothermia—Principles and Practices, Springer, Heidelberg, Germany, 2010.
- A. Szasz, G. Vincze, O. Szasz, and N. Szasz, “An energy analysis of extracellular hyperthermia,” Electromagnetic Biology and Medicine, vol. 22, no. 2-3, pp. 103–115, 2003.
- N. Szasz, Electric field regulation of chondrocyte proliferation, biosynthesis and cellular signalling [Ph.D. thesis], MIT, Cambridge, Mass, USA, 2003.
- G. Vincze, N. Szasz, and A. Szasz, “On the thermal noise limit of cellular membranes,” Bioelectromagnetics, vol. 26, no. 1, pp. 28–35, 2005.
- P. Szendro, G. Vincze, and A. Szasz, “Pink-noise behaviour of biosystems,” European Biophysics Journal, vol. 30, no. 3, pp. 227–231, 2001.
- G. Vincze, A. Szasz, and A. R. Liboff, “New theoretical treatment of ion resonance phenomena,” Bioelectromagnetics, vol. 29, no. 5, pp. 380–386, 2008.
- N. Meggyesházi, G. Andócs, S. Spisák, and T. Krenács, “Early changes in protein expression releated to cancer treatment by modulated electro-hyperthermia,” in Proceedings of the 31st Conference of International Clinical Hyperthermia Society, Budapest, Hungary, 2012.
- M. M. Carreiro, D. C. Laux, and D. R. Nelson, “Characterization of the heat shock response and identification of heat shock protein antigens of Borrelia burgdorferi,” Infection and Immunity, vol. 58, no. 7, pp. 2186–2191, 1990.
- A. Scorpio, P. Johnson, A. Laquerre, and D. R. Nelson, “Subcellular localization and chaperone activities of Borrelia burgdorferi Hsp60 and Hsp70,” Journal of Bacteriology, vol. 176, no. 21, pp. 6449–6456, 1994.
- A. Szasz, O. Szasz, and N. Szasz, “Electro-hyperthermia: a new paradigm in cancer therapy,” Deutsche Zeitschrift fur Onkologie, vol. 33, no. 3, pp. 91–99, 2001.
- N. Meggyeshazi, G. Andocs, and T. Krenacs, “Modulated electro-hyperthermia induced programmed cell death in HT29 colorectal carcinoma xenograft,” Virchows Archiv, vol. 461, supplement 1, pp. S1318–S1312, 2012.
Copyright © 2013 Ortwin Zais. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.